{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:07:34Z","timestamp":1782256054682,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1245\/s10434-024-16625-7","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:02:06Z","timestamp":1733328126000},"page":"2023-2028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of Surgical Overtreatment in cN1 Breast Cancer Patients who Become ypN0 After Neoadjuvant Chemotherapy: SLNB Versus TAD"],"prefix":"10.1245","volume":"32","author":[{"given":"Alison","family":"Laws","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vincuilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"14","key":"16625_CR1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/JAMA.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/JAMA.2013.278932.","journal-title":"JAMA."},{"issue":"3","key":"16625_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201363. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol."},{"issue":"7","key":"16625_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol."},{"issue":"2","key":"16625_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/S10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343\u201352. https:\/\/doi.org\/10.1007\/S10549-018-5004-7.","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"16625_CR5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved Axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"J Clin Oncol."},{"issue":"11","key":"16625_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/JAMASURG.2022.3907","volume":"157","author":"JM Simons","year":"2022","unstructured":"Simons JM, Van Nijnatten TJA, Van Der Pol CC, et al. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. JAMA Surg. 2022;157(11):991\u20139. https:\/\/doi.org\/10.1001\/JAMASURG.2022.3907.","journal-title":"JAMA Surg."},{"key":"16625_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer; Version 2.2024. National Comprehensive Cancer Network."},{"issue":"12","key":"16625_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/JAMAONCOL.2021.4394","volume":"7","author":"AV Barrio","year":"2021","unstructured":"Barrio AV, Montagna G, Mamtani A, et al. Nodal Recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event. JAMA Oncol. 2021;7(12):1851\u20135. https:\/\/doi.org\/10.1001\/JAMAONCOL.2021.4394.","journal-title":"JAMA Oncol."},{"issue":"4","key":"16625_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/J.EJSO.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol. 2021;47(4):804\u201312. https:\/\/doi.org\/10.1016\/J.EJSO.2020.10.014.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"16625_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1245\/S10434-020-09211-0","volume":"28","author":"SM Wong","year":"2021","unstructured":"Wong SM, Basik M, Florianova L, et al. oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2021;28(5):2621\u20139. https:\/\/doi.org\/10.1245\/S10434-020-09211-0.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"16625_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","volume":"10","author":"G Montagna","year":"2024","unstructured":"Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, Barrio AV, van den Bruele AB, Cabioglu N, Sevilimedu V, Rosenberger LH, Hwang ES, Ingham A, Papassotiropoulos B, Nguyen-Str\u00e4uli BD, Kurzeder C, Aybar DD, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Karanlik H, Dedes KJ, Romics L, Banys-Paluchowski M, Muslumanoglu M, Perez MDRC, D\u00edaz MC, Heidinger M, Fehr MK, Reinisch M, Tukenmez M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Paulinelli RR, Zarhi SS, Kuemmel S, Bruzas S, di Lascio S, Parissenti TK, Hoskin TL, G\u00fcth U, Ovalle V, Tausch C, Kuerer HM, Caudle AS, Boileau JF, Boughey JC, K\u00fchn T, Morrow M, Weber WP. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10(6):793\u20138.","journal-title":"JAMA Oncol."},{"issue":"8","key":"16625_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/JAMASURG.2023.1772","volume":"158","author":"S Kuemmel","year":"2023","unstructured":"Kuemmel S, Heil J, Bruzas S, et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158(8):807\u201315. https:\/\/doi.org\/10.1001\/JAMASURG.2023.1772.","journal-title":"JAMA Surg."},{"issue":"11","key":"16625_CR13","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/S10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374. https:\/\/doi.org\/10.1245\/S10434-016-5246-8.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"16625_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","volume":"261","author":"M Donker","year":"2015","unstructured":"Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378\u201382. https:\/\/doi.org\/10.1097\/SLA.0000000000000558.","journal-title":"Ann Surg."},{"issue":"10","key":"16625_CR15","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1245\/S10434-017-6023-Z","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hieken TJ, Glazebrook KN, Boughey JC. Localizing the clipped node in patients with node-positive breast cancer treated with neoadjuvant chemotherapy: early learning experience and challenges. Ann Surg Oncol. 2017;24(10):3011\u20136. https:\/\/doi.org\/10.1245\/S10434-017-6023-Z.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"16625_CR16","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1245\/S10434-020-08902-Y","volume":"27","author":"A Laws","year":"2020","unstructured":"Laws A, Dillon K, Kelly BN, et al. Node-positive patients treated with neoadjuvant chemotherapy can be spared axillary lymph node dissection with wireless non-radioactive localizers. Ann Surg Oncol. 2020;27(12):4819\u201327. https:\/\/doi.org\/10.1245\/S10434-020-08902-Y.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"16625_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/J.EJSO.2018.05.035","volume":"44","author":"S Hartmann","year":"2018","unstructured":"Hartmann S, Reimer T, Gerber B, Stubert J, Stengel B, Stachs A. Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol. 2018;44(9):1307\u201311. https:\/\/doi.org\/10.1016\/J.EJSO.2018.05.035.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"16625_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/CANCERS13071539","volume":"13","author":"PK Swarnkar","year":"2021","unstructured":"Swarnkar PK, Tayeh S, Michell MJ, Mokbel K. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers (Basel). 2021;13(7):1539. https:\/\/doi.org\/10.3390\/CANCERS13071539.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"16625_CR19","doi-asserted-by":"publisher","first-page":"E553","DOI":"10.1097\/SLA.0000000000004572","volume":"276","author":"S Kuemmel","year":"2022","unstructured":"Kuemmel S, Heil J, Rueland A, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg. 2022;276(5):E553\u201362. https:\/\/doi.org\/10.1097\/SLA.0000000000004572.","journal-title":"Ann Surg."},{"issue":"7","key":"16625_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMOA1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive her2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMOA1814017.","journal-title":"N Engl J Med."},{"issue":"22","key":"16625_CR21","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMOA1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMOA1612645.","journal-title":"N Engl J Med."},{"issue":"9","key":"16625_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMOA1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMOA1910549.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16625-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16625-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16625-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:37:55Z","timestamp":1739194675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16625-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["16625"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16625-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EAM reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche\/Genentech; speakers honoraria and travel support from Merck Sharp and Dohme; and institutional research support from Roche\/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK reports speaker honoraria for Exact Sciences and compensated service on the FES Steering Committee, GE Healthcare, and compensated service as faculty for PrecisCa cancer information service. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}